Powerful P2Y12 inhibition after percutaneous coronary intervention for an acute coronary syndrome: “the times they are a changing”

Stefano Savonitto, Luca A. Ferri, Giorgio Bassanelli, Gianluca Tiberti, Luigi Piatti


DAPT using aspirin and a P2Y12 platelet ADP receptor blocker has been established since more than 20 years as the pharmacological background of percutaneous coronary intervention (PCI) and post-acute coronary syndrome (ACS) (Table 1). First, the combination of aspirin and ticlopidine given for 30 days has shown superiority over aspirin and anticoagulant therapy in patients undergoing coronary artery stenting (1).